The following represents disclosure information provided by authors of this abstract. The Gastrointestinal Cancers Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A comparison of biologics in first-line advanced colorectal cancer: A Bayesian network meta-analysis of EGFR inhibitors and bevacizumab.
Alexander Kumachev
No relevant relationships to disclose
Marie Yan
No relevant relationships to disclose
Scott R. Berry
Consultant or Advisory Role - Amgen; Bristol-Myers Squibb; Roche; Sanofi
Honoraria - Amgen; Bristol-Myers Squibb; Roche; Sanofi
Yoo-Joung Ko
Honoraria - Bristol-Myers Squibb; Roche
Maria Carmen Riesco Martinez
No relevant relationships to disclose
Keya Shah
No relevant relationships to disclose
Kelvin K. Chan
No relevant relationships to disclose